Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
CHRS Stock Chart & Stats
$1.36
-$0.05(-3.18%)
At close: 4:00 PM EST
$1.36
-$0.05(-3.18%)
Day’s Range― - ―
52-Week Range$0.71 - $2.43
Previous CloseN/A
Volume565.36K
Average Volume (3M)1.24M
Market Cap
$158.34M
Enterprise Value$53.27M
Total Cash (Recent Filing)$191.66M
Total Debt (Recent Filing)$40.69M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 17, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding120,871,010
10 Day Avg. Volume1,183,990
30 Day Avg. Volume1,237,148
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-1.20
Price to Sales (P/S)0.59
P/FCF Ratio-7.73
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue0.64
Enterprise Value/Gross Profit1.33
Enterprise Value/Ebitda-0.31
Forecast
1Y Price Target
$5.50Price Target Upside304.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$43.82M
Bulls Say, Bears Say
Bulls Say
Financial StabilityWith $238 million in cash, Coherus has financial runway to support operations into 2027, providing stability as it approaches key data events.
Industry RecognitionThe 2025 Nobel Prize spotlight on regulatory T cells highlights the relevance of Coherus' CHS-114, a differentiated anti-CCR8 antibody, drawing interest from larger players in the pharmaceutical industry.
Pipeline ProgressCHS-114, a selective anti-CCR8 antibody, continues to advance across multiple programs with key P1b data catalysts expected in 2026, including 2L head & neck and gastric cancers in 1H26, followed by esophageal (efficacy) and colorectal (initial) readouts in 2H26.
Bears Say
Earnings MissNon-GAAP net loss of $0.33 per share in Q3 was $0.07 worse than our forecast.
Increased ExpensesSG&A and R&D excluding stock-based compensation were $23.3MM and $25.6MM, respectively, vs. our estimates of $20MM and $20MM.
Revenue ShortfallRevenue from Loqtorzi missed the estimated $12.7M and consensus of $13.8M, indicating a shortfall in expected financial performance.
Coherus Biosciences News
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $0.71 and its highest was $2.43 in the past 12 months.
What is Coherus Biosciences’s market cap?
Coherus Biosciences’s market cap is $158.34M.
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Mar 17, 2026 which is in 107 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Nov 06, 2025. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.354 by $0.044.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -0.34.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 120,871,010 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.354. Following the earnings report the stock price went down -10.067%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Currently, no hedge funds are holding shares in CHRS
Coherus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.50 (304.41% Upside)
$5.50 (304.41% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 231.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.28%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus Biosciences, Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutics in the fields of oncology and immunology. The company specializes in biosimilars, which are biologic medical products highly similar to already approved reference products. Coherus aims to provide more affordable treatment options for patients by leveraging its expertise in biologics and regulatory pathways to bring high-quality biosimilar therapies to market.
CHRS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook, with strong financial performance, strategic focus on pipeline development, and effective market expansion strategies. However, some challenges remain in regional sales discrepancies and community physician engagement.View all CHRS earnings summariesCHRS Stock 12 Month Forecast
Average Price Target
$5.50
▲(304.41% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Protalix
―
Seres Therapeutics
―
Genfit SA
―
Innate Pharma
―
Ownership Overview
1.08% Insiders
14.29% Mutual Funds
12.20% Other Institutional Investors
63.25% Public Companies and
Individual Investors